Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) were down 6.1% during mid-day trading on Monday . The stock traded as low as $24.27 and last traded at $23.91. Approximately 99,249 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 161,642 shares. The stock had previously closed at $25.45.
LENZ Therapeutics Price Performance
The company has a fifty day moving average price of $24.23 and a 200-day moving average price of $27.01.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of LENZ. Harbor Capital Advisors Inc. acquired a new position in LENZ Therapeutics in the 4th quarter worth approximately $1,270,000. Parkman Healthcare Partners LLC purchased a new position in LENZ Therapeutics during the third quarter worth about $3,308,000. Barclays PLC boosted its holdings in LENZ Therapeutics by 273.1% in the 3rd quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after purchasing an additional 12,051 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of LENZ Therapeutics in the 3rd quarter worth approximately $743,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after acquiring an additional 81,901 shares during the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.
About LENZ Therapeutics
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Stories
- Five stocks we like better than LENZ Therapeutics
- Stock Sentiment Analysis: How it Works
- Occidental Petroleum: 4 Reasons to Love These Prices
- What is the Hang Seng index?
- Super Micro’s International Presence Makes It a Winning Stock
- How to Plot Fibonacci Price Inflection Levels
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
